Biodesix Inc. (BDSX) Reports In-Line Q4 EPS

Biodesix Inc. (NASDAQ: BDSX) reported Q4 EPS of ($0.49), in-line with the analyst estimate of ($0.49). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $7.3 million.

GUIDANCE:

Biodesix Inc. sees FY2022 revenue of $37.5-39.5 million, versus the consensus of $35.5 million.

For earnings history and earnings-related data on Biodesix Inc. (BDSX) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance